TRD208

TRD208 is a sustained-release formulation of **ropivacaine hydrochloride** developed by Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharmaceutical. It is designed for the management of **postoperative pain** through local infiltration. As a local anesthetic of the amino amide class, ropivacaine works by blocking voltage-gated sodium channels in nerve fibers, which prevents the initiation and conduction of nerve impulses, thereby providing analgesia. The TRD208 formulation utilizes a sustained-release suspension technology (likely lipid-based) to prolong the duration of the anesthetic effect compared to standard ropivacaine injections. This extended duration aims to provide effective pain control for several days following surgery, potentially reducing the requirement for systemic opioids and facilitating faster patient recovery. TRD208 is currently in Phase III clinical trials in China.

Other names

ropivacaine hydrochloride sustained-release injectionropivacaine hydrochloride sustained-release suspension injection